Evidence map›Paper›PMID 38444434›Full record

ArticleFrontiers in public health2024

Current scenario and challenges of clinical pharmacists to implement pharmaceutical care in DRG/DIP payment hospitals in China: a qualitative interview study.

Suyu Gao, Xuanxuan Wang, Yun Lu, Yunkun Liu, Qiaoli Jiang, Jiajia Feng, Weihua Kong, Likai Lin, Hong Cheng

Open access · goldAbstract read
In one paragraph

Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Suyu GaoDepartment of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, China.
Xuanxuan WangDepartment of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, China.
Yun LuDepartment of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, China.
Yunkun LiuDepartment of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, China.
Qiaoli JiangDepartment of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, China.
Jiajia FengHospital Management Institute of Wuhan University, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Weihua KongHospital Management Institute of Wuhan University, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Likai LinHospital Management Institute of Wuhan University, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Hong ChengDepartment of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, China.
Wuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The Diagnosis-Related Group (DRG) or Diagnosis-Intervention Packet (DIP) payment system, now introduced in China, intends to streamline healthcare billing practices. However, its implications for clinical pharmacists, pivotal stakeholders in the healthcare system, remain inadequately explored. This study sought to assess the perceptions, challenges, and roles of clinical pharmacists in China following the introduction of the DRG or DIP payment system. Methods: Qualitative interviews were conducted among a sample of clinical pharmacists. Ten semi-structured interviews were conducted, either online or face to face. Thematic analysis was employed to identify key insights and concerns related to their professional landscape under the DRG or DIP system. Results: Clinical pharmacists exhibited variable awareness levels about the DRG or DIP system. Their roles have undergone shifts, creating a balance between traditional responsibilities and new obligations dictated by the DRG or DIP system. Professional development, particularly concerning health economics and DRG-based or DIP-based patient care, was highlighted as a key need. There were calls for policy support at both healthcare and national levels and a revised, holistic performance assessment system. The demand for more resources, be it in training platforms or personnel, was a recurrent theme. Conclusion: The DRG or DIP system's introduction in China poses both opportunities and challenges for clinical pharmacists. Addressing awareness gaps, offering robust policy support, ensuring adequate resource allocation, and recognizing the evolving role of pharmacists are crucial for harmoniously integrating the DRG or DIP system into the Chinese healthcare paradigm.

Indexed as

Pharmaceutical ServicesPharmacistsChinaDiagnosis-Related GroupsHospitalsHumansQualitative ResearchChinaclinical pharmacistsDiagnosis-Intervention Packet (DIP) payment systemDiagnosis-Related Group payment systemhealthcare policyqualitative interview

Identifiers

PMID38444434
PMCPMC10912177
OpenAlexW4391968277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.